332 related articles for article (PubMed ID: 12505751)
1. Serum levels of non-carboxymethyllysine advanced glycation endproducts are correlated to severity of microvascular complications in patients with Type 1 diabetes.
Miura J; Yamagishi Si; Uchigata Y; Takeuchi M; Yamamoto H; Makita Z; Iwamoto Y
J Diabetes Complications; 2003; 17(1):16-21. PubMed ID: 12505751
[TBL] [Abstract][Full Text] [Related]
2. Relationship between blood levels of N-carboxymethyl-lysine and pentosidine and the severity of microangiopathy in type 2 diabetes.
Hirata K; Kubo K
Endocr J; 2004 Dec; 51(6):537-44. PubMed ID: 15644571
[TBL] [Abstract][Full Text] [Related]
3. Pentosidine and N-carboxymethyl-lysine: biomarkers for type 2 diabetic retinopathy.
Ghanem AA; Elewa A; Arafa LF
Eur J Ophthalmol; 2011; 21(1):48-54. PubMed ID: 20544678
[TBL] [Abstract][Full Text] [Related]
4. Serum levels of advanced glycation end products are associated with left ventricular diastolic function in patients with type 1 diabetes.
Berg TJ; Snorgaard O; Faber J; Torjesen PA; Hildebrandt P; Mehlsen J; Hanssen KF
Diabetes Care; 1999 Jul; 22(7):1186-90. PubMed ID: 10388987
[TBL] [Abstract][Full Text] [Related]
5. Pentosidine as a biomarker for microvascular complications in type 2 diabetic patients.
Kerkeni M; Saïdi A; Bouzidi H; Letaief A; Ben Yahia S; Hammami M
Diab Vasc Dis Res; 2013 May; 10(3):239-45. PubMed ID: 23091285
[TBL] [Abstract][Full Text] [Related]
6. Skin collagen pentosidine and fluorescence in diabetes were predictors of retinopathy progression and creatininemia increase already 6years after punch-biopsy.
Sternberg M; M'bemba J; Urios P; Borsos AM; Selam JL; Peyroux J; Slama G
Clin Biochem; 2016 Feb; 49(3):225-31. PubMed ID: 26506116
[TBL] [Abstract][Full Text] [Related]
7. N(carboxymethyl)lysine as a biomarker for microvascular complications in type 2 diabetic patients.
Wautier MP; Massin P; Guillausseau PJ; Huijberts M; Levy B; Boulanger E; Laloi-Michelin M; Wautier JL
Diabetes Metab; 2003 Feb; 29(1):44-52. PubMed ID: 12629447
[TBL] [Abstract][Full Text] [Related]
8. Plasma levels of pentosidine in diabetic patients: an advanced glycation end product.
Sugiyama S; Miyata T; Ueda Y; Tanaka H; Maeda K; Kawashima S; Van Ypersele de Strihou C; Kurokawa K
J Am Soc Nephrol; 1998 Sep; 9(9):1681-8. PubMed ID: 9727377
[TBL] [Abstract][Full Text] [Related]
9. Improvement in quality of diabetes control and concentrations of AGE-products in patients with type 1 and insulin-treated type 2 diabetes mellitus studied over a period of 10 years (JEVIN).
Schiel R; Franke S; Appel T; Voigt U; Ross IS; Kientsch-Engel R; Stein G; Müller UA
J Diabetes Complications; 2003; 17(2):90-7. PubMed ID: 12614975
[TBL] [Abstract][Full Text] [Related]
10. Pentosidine - a new biochemical marker in diabetic retinopathy.
Salman AG; Mansour DE; Swelem AH; Al-Zawahary WM; Radwan AA
Ophthalmic Res; 2009; 42(2):96-8. PubMed ID: 19546600
[TBL] [Abstract][Full Text] [Related]
11. Impact of metabolic control and serum lipids on the concentration of advanced glycation end products in the serum of children and adolescents with type 1 diabetes, as determined by fluorescence spectroscopy and nepsilon-(carboxymethyl)lysine ELISA.
Galler A; Müller G; Schinzel R; Kratzsch J; Kiess W; Münch G
Diabetes Care; 2003 Sep; 26(9):2609-15. PubMed ID: 12941727
[TBL] [Abstract][Full Text] [Related]
12. Advanced glycation end products in adolescents and young adults with diabetic angiopathy.
Chiarelli F; Catino M; Tumini S; Cipollone F; Mezzetti A; Vanelli M; Verrotti A
Pediatr Nephrol; 2000 Aug; 14(8-9):841-6. PubMed ID: 10955941
[TBL] [Abstract][Full Text] [Related]
13. Serum concentrations of advanced glycation endproducts are associated with the development of atherosclerosis as well as diabetic microangiopathy in patients with type 2 diabetes.
Aso Y; Inukai T; Tayama K; Takemura Y
Acta Diabetol; 2000; 37(2):87-92. PubMed ID: 11194933
[TBL] [Abstract][Full Text] [Related]
14. Increased serum levels of pentosidine, but not carboxymethyl lysine, in type 2 diabetes without obvious diabetic nephropathy.
Daimon M; Ono Y; Saito T; Yamaguchi H; Hirata A; Ohnuma H; Igarashi M; Eguchi H; Manaka H; Kato T
Diabetes Care; 1999 May; 22(5):877-8. PubMed ID: 10332715
[No Abstract] [Full Text] [Related]
15. Diabetic retinopathy risk correlates with intracellular concentrations of the glycoxidation product Nepsilon-(carboxymethyl) lysine independently of glycohaemoglobin concentrations.
Hammes HP; Brownlee M; Lin J; Schleicher E; Bretzel RG
Diabetologia; 1999 May; 42(5):603-7. PubMed ID: 10333054
[TBL] [Abstract][Full Text] [Related]
16. Glycation and carboxymethyllysine levels in skin collagen predict the risk of future 10-year progression of diabetic retinopathy and nephropathy in the diabetes control and complications trial and epidemiology of diabetes interventions and complications participants with type 1 diabetes.
Genuth S; Sun W; Cleary P; Sell DR; Dahms W; Malone J; Sivitz W; Monnier VM;
Diabetes; 2005 Nov; 54(11):3103-11. PubMed ID: 16249432
[TBL] [Abstract][Full Text] [Related]
17. Renal and retinal microangiopathy after 15 years of follow-up study in a sample of Type 1 diabetes mellitus patients.
Romero P; Salvat M; Fernández J; Baget M; Martinez I
J Diabetes Complications; 2007; 21(2):93-100. PubMed ID: 17331857
[TBL] [Abstract][Full Text] [Related]
18. Serum levels of the advanced glycation end products Nepsilon-carboxymethyllysine and pentosidine are not influenced by treatment with the angiotensin receptor II type 1 blocker irbesartan in patients with type 2 diabetic nephropathy and hypertension.
Busch M; Franke S; Wolf G; Rohde RD; Stein G;
Nephron Clin Pract; 2008; 108(4):c291-7. PubMed ID: 18434751
[TBL] [Abstract][Full Text] [Related]
19. The impact of salsalate treatment on serum levels of advanced glycation end products in type 2 diabetes.
Barzilay JI; Jablonski KA; Fonseca V; Shoelson SE; Goldfine AB; Strauch C; Monnier VM;
Diabetes Care; 2014 Apr; 37(4):1083-91. PubMed ID: 24255104
[TBL] [Abstract][Full Text] [Related]
20. Development and Application of Mass Spectroscopy Assays for Nε-(1-Carboxymethyl)-L-Lysine and Pentosidine in Renal Failure and Diabetes.
O'Grady KL; Khosla S; Farr JN; Bondar OP; Atkinson EJ; Achenbach SJ; Eckhardt BA; Thicke BS; Tweed AJ; Volkman TL; Drake MT; Hines JM; Singh RJ
J Appl Lab Med; 2020 May; 5(3):558-568. PubMed ID: 32445362
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
